Moderated Poster

Poster, Podium & Video Sessions

MP31-04: The Power of Crowdsourcing: Novel Method for Discovery of Urine Biomarkers

Saturday, May 13
9:30 AM - 11:30 AM
Location: BCEC: Room 156

Presentation Authors: Michael Chancellor*, Sarah Bartolone, Royal Oak, MI, Interstitial Cystitis Association, McLean, VA, Joseph Janicki, Pittsburgh, PA, Bernadette Zwaans, Abdrew Verneecke, Kenneth Peters, Laura Lamb, Royal Oak, MI

Introduction: Interstitial cystitis/bladder pain syndrome (IC/BPS) has significant unmet medical needs including the lack of an objective laboratory test, such as a urine based biomarker. National collection of adequate patient samples for IC/BPS including normal controls can be challenging. We developed a novel research model that can engage multiple stakeholders and allow fast and broad participation for biomarker development.

Methods: In January 2016, a national crowdsourced research project engaging the entire IC/BPS community was conducted by Beaumont Health researchers in collaboration with the Interstitial Cystitis Association (ICA). This study had Institutional Review Board approval. Announcement of this study through social media was disseminated by the ICA. YouTube videos describing the scope of the project and participant requirements were posted (https://youtu.be/3BlnZdCq5vw and https://youtu.be/GL9T7ISyImk). Questionnaires were completed online through HIPAA compliant Survey Monkey. Special urine containers with preservatives developed to maintain protein and nucleic acid integrity in urine at ambient temperature were sent to consented participants with prepaid return shipping.

Results: Public participation was overwhelming and enrollment was closed within two weeks. Overall, men and women of all age groups submitted samples from 46 US states (Figure 1). Total samples received is illustrated in Figure 2. Multiplex analysis discovered three proteins that were highly statistically significant different between IC with ulcer vs IC without ulcer and normal control.

Conclusions: Crowdsourced research toward biomarker development was shown to be feasible and successful in advancing IC/BPS research. Patients with ulcerative IC/BPS have a different profile of urine proteins than normal and non-ulcerative IC patients. A validated Interstitial Cystitis Ulcer Score (ICUS) has been developed from this crowdsourced research project involving multiple stakeholders in interstitial cystitis.

Source Of Funding: We would like to thank the Taubman family for their generous support of interstitial cystitis research including this project.

Michael B. Chancellor, MD

Beaumont Healt, Oakland University William Beaumot School of Medicine

Michael B Chancellor, MD
Professor of Urology, Oakland University William Beaumont School of Medicine
Director of Aikens Neurourology Research Center, Beaumont Health
Michael.chancellor@beaumont.org


Dr. Chancellor, board-certified by the American Board of Urology, received his medical degree from Medical College of Wisconsin in Milwaukee. Dr. Chancellor completed his residency in urology at the University of Michigan. He subsequently completed his fellowship in neurourology and female urology at Columbia University and College of Physicians and Surgeons in New York. Dr. Chancellor is a world-renowned author and speaker. He has appeared on CNN, in the pages of The Wall Street Journal, and in numerous television and radio interviews.

Dr. Chancellor has written over 600 peer-reviewed articles and book chapters in journals including Journal of Urology, European Urology, Gene Therapy, and Lancet. He has also written 11 books, including Botulinum Toxin in Urology. A prolific author and researcher, Dr. Chancellor has gained national and international recognition in the areas of stem cell and tissue engineering as well as drug discovery. He was one of the first urologist to use botulinum toxin to treat lower urinary tract dysfunction. His inventions founded Cook MyoSite, Inc., which is now conducting multicenter North American trials using adult autologous muscle-derived stem cells to treat stress urinary incontinence. Dr. Chancellor also founded Lipella Pharmaceuticals, Inc., a biopharmaceutical company focusing on localized therapy and advance drug delivery.

Dr. Chancellor has received a number of prestigious awards, including the Paul Zimskind Award from the Society of Urodynamics and Female Urology and Grand Prize in the International Jack Lapides Essay Contest. Dr. Chancellor has received funding from the National Institutes of Health and Department of Definese for over two decades and has trained many of today’s experts in urology.

Presentation(s):

Send Email for Michael Chancellor


Assets

MP31-04: The Power of Crowdsourcing: Novel Method for Discovery of Urine Biomarkers



Attendees who have favorited this

Send Email for The Power of Crowdsourcing: Novel Method for Discovery of Urine Biomarkers